JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Inicio・Lista de Acciones・ADMA Biologics Inc

Search

ADMA Biologics Inc

Cerrado

SectorSanidad

10.5 2.74

Resumen

Variación precio

24h

Actual

Mínimo

10.41

Máximo

10.56

Métricas clave
By Trading Economics
Ingresos	13M 49M
Ventas	4.9M 139M
P/B Media del Sector	18.217 67.147
BPA	0.216
Margen de beneficios	35.483
Empleados	640
EBITDA	14M 65M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+142.48% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.3B 2.5B
Apertura anterior	7.76
Cierre anterior	10.5

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

299 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

N/A / 23.5406 Soporte y Resistencia

ADMA Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 22:17 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 may 2026, 23:47 UTC

Ganancias

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 may 2026, 23:40 UTC

Charlas de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 may 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Shareholders to Own About 51% of Combined Company

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Board Unanimously Endorsed, Supported Deal

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Deal Unanimously Recommended by Vault Board

4 may 2026, 22:39 UTC

Adquisiciones, fusiones, absorciones

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources to Acquire All Ordinary Shares in Vault

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources, Vault Minerals Agree to Merger of Equals

4 may 2026, 22:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 may 2026, 22:26 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 may 2026, 22:02 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 may 2026, 22:00 UTC

Charlas de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 may 2026, 21:52 UTC

Ganancias

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 may 2026, 21:49 UTC

Ganancias

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 may 2026, 21:43 UTC

Ganancias

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 may 2026, 21:41 UTC

Ganancias

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 may 2026, 21:40 UTC

Ganancias

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparación entre iguales

Cambio de precio

ADMA Biologics Inc previsión

Precio Objetivo

By TipRanks

142.48% repunte

Estimación a 12 Meses

Media 25 USD 142.48%

Máximo 30 USD

Mínimo 21 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ADMA Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para ADMA Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 23.5406Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bullish event.

Sentimiento

By Acuity

299 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Otras acciones del sector

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat